Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2022 | Aug. 01, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-38311 | |
Entity Registrant Name | Denali Therapeutics Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 46-3872213 | |
Entity Address, Address Line One | 161 Oyster Point Blvd | |
Entity Address, City or Town | South San Francisco | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94080 | |
City Area Code | 650 | |
Local Phone Number | 866-8548 | |
Title of 12(b) Security | Common Stock, par value $0.01 per share | |
Trading Symbol | DNLI | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding (shares) | 123,348,168 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false | |
Entity Central Index Key | 0001714899 | |
Current Fiscal Year End Date | --12-31 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 155,088 | $ 293,477 |
Short-term marketable securities | 913,580 | 571,930 |
Cost sharing reimbursements due from related party | 357 | 1,226 |
Prepaid expenses and other current assets | 45,575 | 30,601 |
Total current assets | 1,114,600 | 897,234 |
Long-term marketable securities | 94,220 | 425,449 |
Property and equipment, net | 38,703 | 38,865 |
Operating lease right-of-use asset | 29,755 | 30,743 |
Other non-current assets | 15,184 | 11,871 |
Total assets | 1,292,462 | 1,404,162 |
Current liabilities: | ||
Accounts payable | 7,116 | 4,779 |
Accrued compensation | 8,315 | 19,013 |
Accrued clinical and other research & development costs | 16,429 | 15,887 |
Accrued manufacturing costs | 17,929 | 9,955 |
Other accrued costs and current liabilities | 2,076 | 2,857 |
Operating lease liability, current | 5,871 | 5,453 |
Related-party contract liability, current | 290,424 | 292,386 |
Contract liabilities, current | 0 | 27,915 |
Total current liabilities | 348,160 | 378,245 |
Related-party contract liability, less current portion | 552 | 1,295 |
Contract liabilities, less current portion | 3,398 | 3,398 |
Operating lease liability, less current portion | 55,525 | 58,554 |
Other non-current liabilities | 379 | 379 |
Total liabilities | 408,014 | 441,871 |
Commitments and contingencies (Note 6) | ||
Stockholders' equity: | ||
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of June 30, 2022 and December 31, 2021 | 0 | 0 |
Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 123,157,278 shares and 122,283,305 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | 1,558 | 1,548 |
Additional paid-in capital | 1,664,174 | 1,608,238 |
Accumulated other comprehensive loss | (12,274) | (2,499) |
Accumulated deficit | (769,010) | (644,996) |
Total stockholders' equity | 884,448 | 962,291 |
Total liabilities and stockholders’ equity | $ 1,292,462 | $ 1,404,162 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Jun. 30, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Convertible preferred stock, par value (usd per share) | $ 0.01 | $ 0.01 |
Convertible preferred stock, shares authorized (in shares) | 40,000,000 | 40,000,000 |
Convertible preferred stock, shares issued (in shares) | 0 | 0 |
Convertible preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (usd per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 400,000,000 | 400,000,000 |
Common stock, shares issued (in shares) | 123,157,278 | 122,283,305 |
Common stock, shares outstanding (in shares) | 123,157,278 | 122,283,305 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | ||
Collaboration revenue: | |||||
Collaboration revenue from customers | [1] | $ 52,480 | $ 22,936 | $ 94,621 | $ 30,858 |
Other collaboration revenue | 0 | 3 | 0 | 4 | |
Total collaboration revenue | 52,480 | 22,939 | 94,621 | 30,862 | |
Operating expenses: | |||||
Research and development | [2] | 92,737 | 65,711 | 178,835 | 125,918 |
General and administrative | 21,159 | 19,045 | 43,700 | 37,981 | |
Total operating expenses | 113,896 | 84,756 | 222,535 | 163,899 | |
Loss from operations | (61,416) | (61,817) | (127,914) | (133,037) | |
Interest and other income, net | 2,649 | 1,126 | 3,927 | 2,305 | |
Loss before income taxes | (58,767) | (60,691) | (123,987) | (130,732) | |
Income tax expense | (27) | 0 | (27) | 0 | |
Net loss | (58,794) | (60,691) | (124,014) | (130,732) | |
Other comprehensive loss: | |||||
Net unrealized loss on marketable securities, net of tax | (3,023) | (136) | (9,775) | (123) | |
Comprehensive loss | $ (61,817) | $ (60,827) | $ (133,789) | $ (130,855) | |
Net loss per share, basic (usd per share) | $ (0.48) | $ (0.50) | $ (1.01) | $ (1.08) | |
Net loss per share, diluted (usd per share) | $ (0.48) | $ (0.50) | $ (1.01) | $ (1.08) | |
Weighted average number of shares outstanding, basic (in shares) | 123,008,558 | 121,291,435 | 122,842,171 | 121,089,174 | |
Weighted average number of shares outstanding, diluted (in shares) | 123,008,558 | 121,291,435 | 122,842,171 | 121,089,174 | |
[1]Includes related-party collaboration revenue from a customer of $0.5 million and $2.7 million for the three and six months ended June 30, 2022, respectively, and $0.8 million and $1.7 million for the three and six months ended June 30, 2021, respectively.[2]Includes an offset to expense from related-party cost sharing reimbursements of $0.4 million and expense for cost sharing payments to a related party of $2.4 million for the three and six months ended June 30, 2022, respectively, and an offset to expense from related-party cost sharing reimbursements of $1.6 million and $4.1 million for the three and six months ended June 30, 2021, respectively. |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | ||
Collaboration revenue from customers, related party | $ 500 | $ 800 | $ 2,700 | $ 1,700 | |
Research and development | [1] | 92,737 | 65,711 | 178,835 | 125,918 |
Biogen Collaboration Agreement | Biogen Collaborative Arrangement | |||||
Offset to research and development expense, related party cost reimbursement | 400 | $ 1,600 | 400 | $ 4,100 | |
Research and development | $ 2,400 | $ 2,400 | |||
[1]Includes an offset to expense from related-party cost sharing reimbursements of $0.4 million and expense for cost sharing payments to a related party of $2.4 million for the three and six months ended June 30, 2022, respectively, and an offset to expense from related-party cost sharing reimbursements of $1.6 million and $4.1 million for the three and six months ended June 30, 2021, respectively. |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit |
Beginning balance (in shares) at Dec. 31, 2020 | 120,531,333 | ||||
Beginning balance at Dec. 31, 2020 | $ 1,150,531 | $ 1,531 | $ 1,503,660 | $ (245) | $ (354,415) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Issuances under equity incentive plans (in shares) | 652,512 | ||||
Issuances under equity incentive plans | 10,865 | $ 6 | 10,859 | ||
Vesting of restricted stock units (in shares) | 348,107 | ||||
Vesting of restricted stock units | 0 | $ 4 | (4) | ||
Stock-based compensation | 42,164 | 42,164 | |||
Net loss | (130,732) | (130,732) | |||
Other comprehensive income (loss) | (123) | (123) | |||
Ending balance (in shares) at Jun. 30, 2021 | 121,531,952 | ||||
Ending balance at Jun. 30, 2021 | 1,072,705 | $ 1,541 | 1,556,679 | (368) | (485,147) |
Beginning balance (in shares) at Mar. 31, 2021 | 121,147,432 | ||||
Beginning balance at Mar. 31, 2021 | 1,105,353 | $ 1,537 | 1,528,504 | (232) | (424,456) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Issuances under equity incentive plans (in shares) | 317,878 | ||||
Issuances under equity incentive plans | 7,043 | $ 3 | 7,040 | ||
Vesting of restricted stock units (in shares) | 66,642 | ||||
Vesting of restricted stock units | 0 | $ 1 | (1) | ||
Stock-based compensation | 21,136 | 21,136 | |||
Net loss | (60,691) | (60,691) | |||
Other comprehensive income (loss) | (136) | (136) | |||
Ending balance (in shares) at Jun. 30, 2021 | 121,531,952 | ||||
Ending balance at Jun. 30, 2021 | $ 1,072,705 | $ 1,541 | 1,556,679 | (368) | (485,147) |
Beginning balance (in shares) at Dec. 31, 2021 | 122,283,305 | 122,283,305 | |||
Beginning balance at Dec. 31, 2021 | $ 962,291 | $ 1,548 | 1,608,238 | (2,499) | (644,996) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Issuances under equity incentive plans (in shares) | 391,961 | ||||
Issuances under equity incentive plans | 5,865 | $ 5 | 5,860 | ||
Vesting of restricted stock units (in shares) | 482,012 | ||||
Vesting of restricted stock units | 0 | $ 5 | (5) | ||
Stock-based compensation | 50,081 | 50,081 | |||
Net loss | (124,014) | (124,014) | |||
Other comprehensive income (loss) | $ (9,775) | (9,775) | |||
Ending balance (in shares) at Jun. 30, 2022 | 123,157,278 | 123,157,278 | |||
Ending balance at Jun. 30, 2022 | $ 884,448 | $ 1,558 | 1,664,174 | (12,274) | (769,010) |
Beginning balance (in shares) at Mar. 31, 2022 | 122,857,908 | ||||
Beginning balance at Mar. 31, 2022 | 917,927 | $ 1,554 | 1,635,840 | (9,251) | (710,216) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Issuances under equity incentive plans (in shares) | 240,542 | ||||
Issuances under equity incentive plans | 4,402 | $ 3 | 4,399 | ||
Vesting of restricted stock units (in shares) | 58,828 | ||||
Vesting of restricted stock units | 0 | $ 1 | (1) | ||
Stock-based compensation | 23,936 | 23,936 | |||
Net loss | (58,794) | (58,794) | |||
Other comprehensive income (loss) | $ (3,023) | (3,023) | |||
Ending balance (in shares) at Jun. 30, 2022 | 123,157,278 | 123,157,278 | |||
Ending balance at Jun. 30, 2022 | $ 884,448 | $ 1,558 | $ 1,664,174 | $ (12,274) | $ (769,010) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Operating activities | ||
Net loss | $ (124,014) | $ (130,732) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 4,151 | 4,312 |
Stock–based compensation expense | 50,081 | 42,164 |
Net amortization of premiums on marketable securities | 2,118 | 3,656 |
Non-cash adjustment to operating lease expense | (1,623) | (1,419) |
Other non-cash items | 5 | 0 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other assets | (14,751) | (8,055) |
Accounts payable | 2,087 | 3,001 |
Accruals and other current liabilities | (2,441) | (9,527) |
Contract liabilities | (27,915) | (6,175) |
Related-party contract liability | (2,705) | (1,686) |
Net cash used in operating activities | (115,007) | (104,461) |
Investing activities | ||
Purchases of marketable securities | (505,460) | (847,296) |
Purchases of property and equipment | (6,934) | (3,572) |
Maturities and sales of marketable securities | 483,147 | 923,000 |
Net cash (used in) provided by investing activities | (29,247) | 72,132 |
Financing activities | ||
Proceeds from exercise of awards under equity incentive plans | 5,865 | 10,865 |
Net cash provided by financing activities | 5,865 | 10,865 |
Net decrease in cash, cash equivalents and restricted cash | (138,389) | (21,464) |
Cash, cash equivalents and restricted cash at beginning of period | 294,977 | 508,644 |
Cash, cash equivalents and restricted cash at end of period | 156,588 | 487,180 |
Supplemental disclosures of cash flow information | ||
Property and equipment purchases accrued but not yet paid | $ 321 | $ 229 |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | Significant Accounting Policies Organization and Description of Business Denali Therapeutics Inc. ("Denali" or the “Company”) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on February 28, 2022 (the "2021 Annual Report on Form 10-K"). The Condensed Consolidated Balance Sheet as of December 31, 2021 was derived from the audited annual consolidated financial statements as of and for the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards, if any, discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. During the six months ended June 30, 2022 there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2021 Annual Report on Form 10-K. For further information with regard to the Company’s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company’s Consolidated Financial Statements included in the 2021 Annual Report on Form 10-K. Principles of Consolidation These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. For the Company and its subsidiaries, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates, non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates, and transactions in foreign currencies are remeasured at average exchange rates. Foreign currency gains and losses resulting from remeasurement are recognized in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company’s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of June 30, 2022 and December 31, 2021, the Company had no off-balance sheet concentrations of credit risk. The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Further, the company is also subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages. Segments The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents are reported at fair value. Cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Statements of Cash Flows is composed of Cash and Cash equivalents reported in the Condensed Consolidated Balance Sheets and $1.5 million of restricted cash for the letter of credit for the Company’s headquarters building lease, which is included within other non-current assets in the Condensed Consolidated Balance Sheets. Marketable Securities The Company generally invests its excess cash in money market funds and investment grade short to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities, or long-term marketable securities on the Condensed Consolidated Balance Sheets, are considered available-for-sale, and reported at fair value with net unrealized gains and losses included as a component of stockholders’ equity. The Company classifies investments in securities with remaining maturities of less than one year, or where its intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. The Company classifies investments in securities with remaining maturities of over one year as long-term investments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses and declines in value determined to be due to credit losses on marketable securities, if any, are included in interest and other income, net. The Company periodically evaluates the need for an allowance for credit losses. This evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security. Accounts Receivable Accounts receivable are included within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. The accounts receivable balance represents amounts receivable from the Company's collaboration partners, excluding related parties, net of an allowance for credit losses, if required. Leases The Company leases real estate, and certain equipment for use in its operations. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (“ROU”) asset and operating lease liability is recognized for identified operating leases in the Condensed Consolidated Balance Sheets. The changes in operating lease ROU assets and operating lease liabilities are presented net within non-cash adjustment to operating lease expense in the Condensed Consolidated Statements of Cash Flows. ROU assets represent the Company’s right to use the underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate on the date of lease commencement, or the rate implicit in the lease, if known. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component. Revenue Recognition License, Option and Collaboration Revenue The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606. The accounting treatment pursuant to Topic 606 is outlined below. The terms of license, option and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; option exercise fees; development, regulatory and commercial milestone payments; payments for manufacturing supply and research and development services and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company may also receive reimbursement or make payments to a collaboration partner to satisfy cost sharing requirements. These payments are accounted for pursuant to ASC 808 and are recorded as an offset or increase to research and development expenses, respectively. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company’s Condensed Consolidated Balance Sheets. If the related performance obligation is expected to be satisfied within the next 12 months this will be classified in current liabilities. Amounts recognized as revenue prior to the Company having an unconditional right (other than a right that is conditioned only on the passage of time) to receipt are recorded as contract assets in the Company's Condensed Consolidated Balance Sheets. If the Company expects to have an unconditional right to receive the consideration in the next 12 months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the promised good or service does not provide the customer with a material right. The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP"). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception, or to a single performance obligation as applicable. Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations. Comprehensive Loss Comprehensive loss is composed of net loss and certain changes in stockholders’ equity that are excluded from net loss, primarily unrealized gains or losses on the Company’s marketable securities. Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands): June 30, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 93,062 $ — $ — $ 93,062 Short-term marketable securities: U.S. government treasuries 786,315 — — 786,315 Corporate debt securities — 60,913 — 60,913 Commercial paper — 66,352 — 66,352 Long-term marketable securities: U.S. government treasuries 92,279 — — 92,279 Corporate debt securities — 1,941 — 1,941 Total $ 971,656 $ 129,206 $ — $ 1,100,862 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 265,294 $ — $ — $ 265,294 Short-term marketable securities: U.S. government treasuries 450,436 — — 450,436 Corporate debt securities — 70,009 — 70,009 Commercial paper — 51,485 — 51,485 Long-term marketable securities: U.S. government treasuries 410,147 — — 410,147 Corporate debt securities — 15,302 — 15,302 Total $ 1,125,877 $ 136,796 $ — $ 1,262,673 Liabilities: Foreign currency derivative contracts $ — $ 111 $ — $ 111 Total $ — $ 111 $ — $ 111 The carrying amounts of cost sharing reimbursements due from related party, prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate their fair values due to their short-term maturities. The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly. The Company has not transferred any assets or liabilities between the fair value measurement levels. |
Marketable Securities
Marketable Securities | 6 Months Ended |
Jun. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Marketable Securities | Marketable Securities All marketable securities were considered available-for-sale at June 30, 2022 and December 31, 2021. On a recurring basis, the Company records its marketable securities at fair value using Level 1 or Level 2 inputs as disclosed in Note 2, "Fair Value Measurements". The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands): June 30, 2022 Amortized Cost Unrealized Holding Gains Unrealized Holding Losses Aggregate Fair Value Short-term marketable securities: U.S. government treasuries (1) $ 794,785 $ 1 $ (8,471) $ 786,315 Corporate debt securities (2) 61,483 — (570) 60,913 Commercial paper 66,352 — — 66,352 Total short-term marketable securities 922,620 1 (9,041) 913,580 Long-term marketable securities: U.S. government treasuries (3) 95,099 — (2,820) 92,279 Corporate debt securities (4) 2,004 — (63) 1,941 Total long-term marketable securities 97,103 — (2,883) 94,220 Total $ 1,019,723 $ 1 $ (11,924) $ 1,007,800 __________________________________________________ (1) Unrealized holding losses on 55 securities with an aggregate fair value of $746.8 million. (2) Unrealized holding losses on 17 securities with an aggregate fair value of $60.9 million. (3) Unrealized holding losses on 6 securities with an aggregate fair value of $92.3 million. (4) Unrealized holding losses on 1 security with an aggregate fair value of $1.9 million. December 31, 2021 Amortized Cost Unrealized Holding Gains Unrealized Holding Losses Aggregate Fair Value Short-term marketable securities: U.S. government treasuries (1) $ 450,689 $ — $ (253) $ 450,436 Corporate debt securities (2) 70,076 1 (68) 70,009 Commercial paper 51,485 — — 51,485 Total short-term marketable securities 572,250 1 (321) 571,930 Long-term marketable securities: U.S. government treasuries (3) 411,904 — (1,757) 410,147 Corporate debt securities (4) 15,373 — (71) 15,302 Total long-term marketable securities 427,277 — (1,828) 425,449 Total $ 999,527 $ 1 $ (2,149) $ 997,379 __________________________________________________ (1) Unrealized holding losses on 19 securities with an aggregate fair value of $450.4 million. (2) Unrealized holding losses on 16 securities with an aggregate fair value of $68.5 million. (3) Unrealized holding losses on 16 securities with an aggregate fair value of $410.1 million. (4) Unrealized holding losses on 6 securities with an aggregate fair value of $15.3 million. As of June 30, 2022 and December 31, 2021, a majority of the Company's marketable securities were in an unrealized loss position. The Company has not recognized an allowance for credit losses as of June 30, 2022 or December 31, 2021. The Company determined that it had the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. Further, these marketable securities were initially, and continue to be, held with investment grade, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date have been in a loss position for less than 12 months or the loss is not material. |
Collaboration Agreements
Collaboration Agreements | 6 Months Ended |
Jun. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaboration Agreements | Collaboration Agreements Biogen In August 2020, the Company entered into a binding Provisional Collaboration and License Agreement (“Provisional Biogen Collaboration Agreement”) with Biogen Inc.’s subsidiaries, Biogen MA Inc. (“BIMA”) and Biogen International GmbH (“BIG”) (BIMA and BIG, collectively, “Biogen”), which expired in October 2020 upon the execution of a Definitive LRRK2 Collaboration and License Agreement (“LRRK2 Agreement”) with Biogen on October 4, 2020 and a Right of First Negotiation, Option and License Agreement (the “ROFN and Option Agreement”) on October 6, 2020 (collectively, the "Biogen Collaboration Agreement"). The details of the Provisional Biogen Collaboration Agreement and the Biogen Collaboration Agreement and the payments the Company has received, and is entitled to receive, are further described in Note 6, "Collaboration Agreements", to the consolidated financial statements in the 2021 Annual Report on Form 10-K. During the second quarter of 2022, there were no changes to the terms of the Company’s collaboration agreement with Biogen, and no change in the transaction price for the Biogen Collaboration Agreement has been recorded during the three and six months ended June 30, 2022. A related-party contract liability of $291.0 million and $293.7 million was recorded on the Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021, respectively. Approximately $288.9 million of the June 30, 2022 contract liability relates to the revenue allocated to the material right for an option under the ROFN and Option Agreement which is being deferred until resolution of the option, which is expected to be within one year of the balance sheet date, and $2.1 million of this contract liability relates to the portion of the Option Research Services performance obligation yet to be satisfied, with such amount to be recognized over the estimated period of the services, which is expected to be more than one year. The Company recorded an offset to research and development expenses for LRRK2 Development Activities of $0.4 million, and incremental research and development expenses for LRRK2 Development Activities of $2.4 million for cost sharing reimbursement and payments, respectively, for the three and six months ended June 30, 2022, respectively. The Company recorded $0.4 million of cost sharing reimbursements due from related party on the Condensed Consolidated Balance Sheet as of June 30, 2022. The Company recorded $1.6 million and $4.1 million of cost sharing reimbursements for LRRK2 Development Activities as an offset to research and development expenses in the Condensed Consolidated Statement of Operations and Comprehensive Loss for the three and six months ended June 30, 2021, respectively, and $1.2 million was recorded as cost sharing reimbursements due from related party on the Condensed Consolidated Balance Sheets as of December 31, 2021. As of June 30, 2022, the Company had not achieved any milestones and had not recorded any product sales under the Biogen Collaboration Agreement. Sanofi In October 2018, the Company entered into a Collaboration and License Agreement ("Sanofi Collaboration Agreement") with Genzyme Corporation, a wholly owned subsidiary of Sanofi S.A. ("Sanofi"). The details of the Sanofi Collaboration Agreement and the payments the Company has received, and is entitled to receive, are further described in Note 6, "Collaboration Agreements", to the consolidated financial statements in the Company's 2021 Annual Report on Form 10-K. During the second quarter of 2022, there were no changes to the terms of the Company’s collaboration agreement with Sanofi. The transaction price of the Sanofi Collaboration Agreement increased by $40.0 million during the three and six months ended June 30, 2022 related to a $40.0 million milestone triggered in April 2022 upon first patient in a Phase 2 study of SAR443820/DNL788 in individuals with amyotrophic lateral sclerosis (ALS) which was paid in May 2022 . A contract liability of $3.4 million was recorded on the Condensed Consolidated Balance Sheets as of both June 30, 2022 and December 31, 2021. This contract liability relates to the portion of the Alzheimer's Disease Services performance obligation yet to be satisfied, with such amounts to be recognized over the estimated period of the services, which is expected to be several years. The Company recorded no receivable associated with the Sanofi Collaboration Agreement on the Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021, respectively. As of June 30, 2022, the Company had earned milestone payments of $65.0 million and had not recorded any product sales under the Sanofi Collaboration Agreement. Takeda Takeda Collaboration Agreement In January 2018, the Company entered into a Collaboration and Option Agreement ("Takeda Collaboration Agreement") with Takeda Pharmaceutical Company Limited ("Takeda"). The details of the Takeda Collaboration Agreement are further described in Note 6, "Collaboration Agreements", to the consolidated financial statements in the Company's 2021 Annual Report on Form 10-K. Total preclinical milestone payments that Takeda may owe to the Company is $55.0 million, all of which were earned, and $43.0 million of which received as of June 30, 2022. A contract liability of $27.9 million was recorded on the Condensed Consolidated Balance Sheets as of December 31, 2021 which was recognized in its entirety during the first quarter of 2022. No contract liability remains on the Condensed Consolidated Balance Sheets as of June 30, 2022. The transaction price of the Takeda Collaboration Agreement increased by $12.0 million and $24.0 million during the three and six months ended June 30, 2022, respectively, due to two $12.0 million preclinical milestones becoming unconstrained and recorded as collaboration revenue from customers in the six months ended June 30, 2022, The first milestone was earned in January 2022 upon approval of the TAK-594/DNL593 ("PTV:PGRN") clinical trial application (CTA), and the second milestone was earned in June 2022 upon approval of the TAK-920/DNL919 ("ATV:TREM2") CTA. Payment for the PTV:PGRN milestone was received in February 2022, and the $12.0 million milestone payment for ATV:TREM2 was recorded as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as of June 30, 2022 and received in July 2022. There was no receivable under the Takeda Collaboration Agreement as of December 31, 2021. The Company has no remaining performance obligations under the Takeda Collaboration Agreement. As of June 30, 2022, the Company had earned $55.0 million in preclinical milestone payments from Takeda, and had not recorded any product sales under the Takeda Collaboration Agreement. PTV:PGRN and ATV:TREM2 Collaboration Agreements Opt-in by Takeda on the PTV:PGRN and ATV:TREM2 programs represented two new contracts with a customer for accounting purposes (the "PTV:PGRN Collaboration Agreement" and the "ATV:TREM2 Collaboration Agreement"), both effective in December 2021. The details of the PTV:PGRN Collaboration Agreement and the ATV:TREM2 Collaboration Agreement are further described in Note 6, "Collaboration Agreements", to the consolidated financial statements in the Company's 2021 Annual Report on Form 10-K. During the three and six months ended June 30, 2022, there were no changes to the terms of either the PTV:PGRN Collaboration Agreement or the ATV:TREM2 Collaboration Agreement and no changes to the transaction prices for either agreement. Under the PTV:PGRN Collaboration Agreement and the ATV:TREM2 Collaboration Agreement, Takeda may be obligated to pay the Company up to an aggregate of $280.0 million upon achievement of certain clinical milestone events and up to an aggregate of $200.0 million in regulatory milestone events relating to receipt of regulatory approval in the United States, certain European countries and Japan. Takeda may also be obligated to pay the Company up to $75.0 million per biologic product upon achievement of a certain sales-based milestone, or an aggregate of $150.0 million if one biologic product from each program achieves this milestone. The Company recorded $2.8 million and $5.7 million of cost sharing reimbursements for PTV:PGRN Development Activities, and $1.5 million and $3.6 million of cost sharing reimbursements for ATV:TREM2 Development Activities, for the three and six months ended June 30, 2022, respectively, as offsets to research and development expenses in the Condensed Consolidated Statement of Operations and Comprehensive Loss. The cost sharing reimbursements for the three months ended June 30, 2022 are recorded as a receivable within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheet as of June 30, 2022. There were no cost sharing reimbursements for the three and six months ended June 30, 2021. As of June 30, 2022, the Company has earned $10.0 million in option fee payments from Takeda, but has not recorded any product sales under either the PTV:PGRN or the ATV:TREM2 Collaboration Agreements. Collaboration Revenue Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Takeda Collaboration Agreement: Takeda Collaboration Agreement Services (1) $ 12,000 $ 7,142 $ 51,916 $ 14,172 Total Takeda Collaboration Revenue 12,000 7,142 51,916 14,172 Sanofi Collaboration Agreement CNS program license 40,000 — 40,000 — Peripheral Program License — 15,000 — 15,000 Alzheimer's Disease Services (2) — 3 — 4 Total Sanofi Collaboration Revenue 40,000 15,003 40,000 15,004 Biogen Collaboration Agreement Option Research Services (2) 480 794 2,705 1,686 Total Biogen Collaboration Revenue 480 794 2,705 $ 1,686 Total Collaboration Revenue $ 52,480 $ 22,939 $ 94,621 $ 30,862 _________________________________________________ (1) Revenue of $27.9 million and $11.8 million for the six months ended June 30, 2022 and 2021, respectively, were included in the contract liability balance at the beginning of the period. No revenue for the three months ended June 30, 2022, and all revenue for the three months ended June 30, 2021, were included in the contract liability balance at the beginning of the respective period. (2) Revenue for the three and six months ended June 30, 2022 and June 30, 2021 represent amounts that were included in the contract liability balance at the beginning of the respective period. |
License Agreements
License Agreements | 6 Months Ended |
Jun. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
License Agreements | License Agreements Genentech In June 2016, the Company entered into an Exclusive License Agreement with Genentech, Inc. (“Genentech License Agreement”). The details of the Genentech License Agreement are further described in Note 7, "License Agreements", to the consolidated financial statements in the Company's 2021 Annual Report on Form 10-K. In June 2022, the Company paid Genentech a $7.5 million clinical milestone payment triggered upon the commencement of dosing in the global Phase 2b LUMA study to evaluate the efficacy and safety of BIIB122/DNL151 by the Company's collaboration partner Biogen. Biogen is responsible for 50% of any payment obligation to Genentech under the Biogen Collaboration Agreement, including this clinical milestone, and accordingly $3.8 million of research and development expense was recorded in the three and six months ended June 30, 2022 . There were no expenses recorded under the Genentech License Agreement for three and six months ended June 30, 2021. To date, the Company has made payments to Genentech of $20.0 million in the aggregate, including an upfront fee, a technology transfer fee and two clinical milestone payments, with $16.3 million of this recorded as research and development expense as incurred, after cost sharing reimbursements from Biogen. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Lease Obligations In May 2018, the Company entered into an operating lease for its corporate headquarters in South San Francisco (the "Headquarters Lease"), as further described in Note 9, "Commitments and Contingencies," to the consolidated financial statements in the Company's 2021 Annual Report on Form 10-K. In August 2021, the Company entered into an operating lease for laboratory, office and warehouse premises in Salt Lake City, Utah (the “SLC Lease”). There was an amendment to the SLC Lease in July 2022, subsequent to which the rentable square feet is approximately 78,000, the contractual term is approximately 9.3 years which will commence upon completion of certain improvements by the landlord and the Company, and future undiscounted lease payments total approximately $20.0 million. For accounting purposes, the SLC lease, as amended, has not yet commenced as the landlord has not yet made the underlying asset available for use by Denali, and as such, no lease liability or ROU asset is recorded on the Condensed Consolidated Balance Sheets as of June 30, 2022, and no operating lease expense has been recorded for the three and six months ended June 30, 2022. Management exercised judgment in applying the requirements of ASC 842, including the determination as to whether certain contracts contain a lease and for leases identified under the standard, the discount rate used to determine the measurement of the lease liability. The discount rate of our operating leases are an approximation of the Company's incremental borrowing rate and are dependent upon the term and economics of the agreement. To estimate the incremental borrowing rates, management considers observable debt yields of comparable market instruments, as well as benchmarks within the lease agreement that may be indicative of the rate implicit in the lease. There were no changes to the terms of the Company's operating leases recognized under ASC 842 during the three or six months ended June 30, 2022. The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating lease cost (1) $ 2,688 $ 2,777 $ 5,551 $ 5,566 Cash paid for amounts included in measurement of lease liability $ 2,676 $ 2,563 $ 5,294 $ 5,099 As of June 30, 2022 2021 Weighted average remaining lease term 6.8 years 7.8 years Weighted average discount rate 9% 9% __________________________________________________ (1) Including variable and short-term lease costs The following table reconciles the undiscounted cash flows for the next five years and total of the remaining years to the operating lease liability recorded in the Condensed Consolidated Balance Sheet as of June 30, 2022 (in thousands): Year Ended December 31: 2022 (six months) 5,408 2023 11,053 2024 11,417 2025 11,793 2026 12,182 Thereafter 29,966 Total undiscounted lease payments 81,819 Present value adjustment (20,423) Net operating lease liabilities $ 61,396 Sublease In October 2018, the Company entered into a sublease agreement ("Sublease Agreement") for space in the corporate headquarters. The details of the Sublease Agreement are further described in Note 9, "Commitments and Contingencies", to the consolidated financial statements in the Company's 2021 Annual Report on Form 10-K. During the second quarter of 2022, there were no changes to the terms of the Sublease Agreement. Total sublease income, including rent and variable sublease cost reimbursements, of $0.9 million and $1.0 million for the three months ended June 30, 2022 and 2021, respectively, and $1.9 million for both the six months ended June 30, 2022 and 2021, was recorded within Interest and other income, net in the Condensed Consolidated Statement of Operations and Comprehensive Loss. The following table details the future undiscounted cash inflows relating to the Sublease Agreement as of June 30, 2022 (in thousands): Year Ended December 31: 2022 (six months) 1,516 2023 3,096 2024 876 2025 and thereafter — Total undiscounted sublease receipts $ 5,488 Indemnification In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company’s Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations and Comprehensive Loss, or Condensed Consolidated Statements of Cash Flows. Commitments Effective September 2017, the Company entered into a Development and Manufacturing Services Agreement as amended (“DMSA”) with Lonza Sales AG (“Lonza”) for the development and manufacture of biologic products. Under the DMSA, the Company will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of the Company's antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. Unless earlier terminated, the DMSA will expire on the later of September 6, 2022 or when all development and manufacturing services are completed. As of June 30, 2022 and December 31, 2021, the Company had open purchase orders for biological product development and manufacturing costs totaling $41.4 million and $35.8 million, respectively. The activities under these purchase orders are expected to be completed by November 2026. As of June 30, 2022 and December 31, 2021, the Company had total non-cancellable purchase commitments under the DMSA of $25.2 million and $28.3 million, respectively. During the three months ended June 30, 2022 and 2021, the Company incurred costs of $9.5 million and $3.2 million, respectively, and made payments of $7.0 million and $5.7 million, respectively, for the development and manufacturing services rendered under the DMSA. During the six months ended June 30, 2022 and 2021, the Company incurred costs of $19.5 million and $8.4 million, respectively, and made payments of $15.7 million and $6.4 million, respectively, for the development and manufacturing services rendered under the DMSA. Contingencies From time to time, the Company may be involved in lawsuits, arbitration, claims, investigations and proceedings consisting of intellectual property, employment and other matters which arise in the ordinary course of business. The Company records accruals for loss contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. |
Stock-Based Awards
Stock-Based Awards | 6 Months Ended |
Jun. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Stock-Based Awards | Stock-Based AwardsThe Company has issued stock-based awards from various equity incentive and stock purchase plans, as more fully described in Note 10, "Stock-Based Awards" to the consolidated financial statements in the Company's 2021 Annual Report on Form 10-K. Stock Option Activity The following table summarizes stock option activity for the six months ended June 30, 2022: Number of Options Weighted-Average Exercise Price Balance at December 31, 2021 13,686,386 $ 24.33 Granted 2,099,590 43.97 Exercised (279,173) 12.66 Forfeited (348,281) 37.46 Balance at June 30, 2022 15,158,522 $ 26.96 Vested and expected to vest at June 30, 2022 13,485,327 $ 30.22 Exercisable at June 30, 2022 9,431,675 $ 20.27 The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions: Six Months Ended June 30, 2022 2021 Expected term (in years) 5.50 - 6.08 5.50 - 6.08 Volatility 65.1% - 66.1% 62.2% - 63.7% Risk-free interest rate 1.5% - 3.0% 0.5% - 1.1% Dividend yield — — Restricted Stock Activity The following table summarizes restricted stock unit ("RSU") activity for the six months ended June 30, 2022: Number of RSU shares Weighted-Average Fair Value at Date of Grant per Share Unvested at December 31, 2021 2,629,980 $ 43.97 Granted 890,606 43.98 Vested and released (482,012) 43.44 Forfeited (139,832) 45.99 Unvested and expected to vest at June 30, 2022 2,898,742 $ 43.96 Stock-Based Compensation Expense The Company’s results of operations include expenses relating to stock-based compensation as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 14,872 $ 12,509 $ 30,428 $ 24,823 General and administrative 9,064 8,627 19,653 17,341 Total $ 23,936 $ 21,136 $ 50,081 $ 42,164 |
Net Loss Per Share
Net Loss Per Share | 6 Months Ended |
Jun. 30, 2022 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | Net Loss Per Share Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. Potentially dilutive securities, including all options issued and outstanding, ESPP shares issuable, and restricted shares subject to future vesting, that were not included in the diluted per share calculations for all periods presented because they would be anti-dilutive totaled approximately 18.4 million and 16.7 million shares as of June 30, 2022 and June 30, 2021, respectively. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Organization and Description of Business | Organization and Description of Business Denali Therapeutics Inc. ("Denali" or the “Company”) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California. |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on February 28, 2022 (the "2021 Annual Report on Form 10-K"). The Condensed Consolidated Balance Sheet as of December 31, 2021 was derived from the audited annual consolidated financial statements as of and for the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards, if any, discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. |
Principles of Consolidation | Principles of Consolidation These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. For the Company and its subsidiaries, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates, non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates, and transactions in foreign currencies are remeasured at average exchange rates. Foreign currency gains and losses resulting from remeasurement are recognized in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss. |
Concentration of Credit Risk and Other Risks and Uncertainties | Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company’s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of June 30, 2022 and December 31, 2021, the Company had no off-balance sheet concentrations of credit risk. The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Further, the company is also subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages. |
Segments | Segments The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources. |
Cash, Cash Equivalents and Restricted Cash | Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents are reported at fair value. |
Marketable Securities | Marketable Securities The Company generally invests its excess cash in money market funds and investment grade short to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities, or long-term marketable securities on the Condensed Consolidated Balance Sheets, are considered available-for-sale, and reported at fair value with net unrealized gains and losses included as a component of stockholders’ equity. The Company classifies investments in securities with remaining maturities of less than one year, or where its intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. The Company classifies investments in securities with remaining maturities of over one year as long-term investments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest and other income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses and declines in value determined to be due to credit losses on marketable securities, if any, are included in interest and other income, net. The Company periodically evaluates the need for an allowance for credit losses. This evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security. |
Accounts Receivable | Accounts Receivable Accounts receivable are included within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. The accounts receivable balance represents amounts receivable from the Company's collaboration partners, excluding related parties, net of an allowance for credit losses, if required. |
Leases | Leases The Company leases real estate, and certain equipment for use in its operations. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (“ROU”) asset and operating lease liability is recognized for identified operating leases in the Condensed Consolidated Balance Sheets. The changes in operating lease ROU assets and operating lease liabilities are presented net within non-cash adjustment to operating lease expense in the Condensed Consolidated Statements of Cash Flows. |
Revenue Recognition | Revenue Recognition License, Option and Collaboration Revenue The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606. The accounting treatment pursuant to Topic 606 is outlined below. The terms of license, option and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; option exercise fees; development, regulatory and commercial milestone payments; payments for manufacturing supply and research and development services and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company may also receive reimbursement or make payments to a collaboration partner to satisfy cost sharing requirements. These payments are accounted for pursuant to ASC 808 and are recorded as an offset or increase to research and development expenses, respectively. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company’s Condensed Consolidated Balance Sheets. If the related performance obligation is expected to be satisfied within the next 12 months this will be classified in current liabilities. Amounts recognized as revenue prior to the Company having an unconditional right (other than a right that is conditioned only on the passage of time) to receipt are recorded as contract assets in the Company's Condensed Consolidated Balance Sheets. If the Company expects to have an unconditional right to receive the consideration in the next 12 months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the promised good or service does not provide the customer with a material right. The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP"). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception, or to a single performance obligation as applicable. Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is composed of net loss and certain changes in stockholders’ equity that are excluded from net loss, primarily unrealized gains or losses on the Company’s marketable securities. |
Net Loss per Share | Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of Assets and Liabilities Measured at Fair Value | Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands): June 30, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 93,062 $ — $ — $ 93,062 Short-term marketable securities: U.S. government treasuries 786,315 — — 786,315 Corporate debt securities — 60,913 — 60,913 Commercial paper — 66,352 — 66,352 Long-term marketable securities: U.S. government treasuries 92,279 — — 92,279 Corporate debt securities — 1,941 — 1,941 Total $ 971,656 $ 129,206 $ — $ 1,100,862 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 265,294 $ — $ — $ 265,294 Short-term marketable securities: U.S. government treasuries 450,436 — — 450,436 Corporate debt securities — 70,009 — 70,009 Commercial paper — 51,485 — 51,485 Long-term marketable securities: U.S. government treasuries 410,147 — — 410,147 Corporate debt securities — 15,302 — 15,302 Total $ 1,125,877 $ 136,796 $ — $ 1,262,673 Liabilities: Foreign currency derivative contracts $ — $ 111 $ — $ 111 Total $ — $ 111 $ — $ 111 |
Marketable Securities (Tables)
Marketable Securities (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Summary of Available for Sale Securities | The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands): June 30, 2022 Amortized Cost Unrealized Holding Gains Unrealized Holding Losses Aggregate Fair Value Short-term marketable securities: U.S. government treasuries (1) $ 794,785 $ 1 $ (8,471) $ 786,315 Corporate debt securities (2) 61,483 — (570) 60,913 Commercial paper 66,352 — — 66,352 Total short-term marketable securities 922,620 1 (9,041) 913,580 Long-term marketable securities: U.S. government treasuries (3) 95,099 — (2,820) 92,279 Corporate debt securities (4) 2,004 — (63) 1,941 Total long-term marketable securities 97,103 — (2,883) 94,220 Total $ 1,019,723 $ 1 $ (11,924) $ 1,007,800 __________________________________________________ (1) Unrealized holding losses on 55 securities with an aggregate fair value of $746.8 million. (2) Unrealized holding losses on 17 securities with an aggregate fair value of $60.9 million. (3) Unrealized holding losses on 6 securities with an aggregate fair value of $92.3 million. (4) Unrealized holding losses on 1 security with an aggregate fair value of $1.9 million. December 31, 2021 Amortized Cost Unrealized Holding Gains Unrealized Holding Losses Aggregate Fair Value Short-term marketable securities: U.S. government treasuries (1) $ 450,689 $ — $ (253) $ 450,436 Corporate debt securities (2) 70,076 1 (68) 70,009 Commercial paper 51,485 — — 51,485 Total short-term marketable securities 572,250 1 (321) 571,930 Long-term marketable securities: U.S. government treasuries (3) 411,904 — (1,757) 410,147 Corporate debt securities (4) 15,373 — (71) 15,302 Total long-term marketable securities 427,277 — (1,828) 425,449 Total $ 999,527 $ 1 $ (2,149) $ 997,379 __________________________________________________ (1) Unrealized holding losses on 19 securities with an aggregate fair value of $450.4 million. (2) Unrealized holding losses on 16 securities with an aggregate fair value of $68.5 million. (3) Unrealized holding losses on 16 securities with an aggregate fair value of $410.1 million. (4) Unrealized holding losses on 6 securities with an aggregate fair value of $15.3 million. |
Collaboration Agreements (Table
Collaboration Agreements (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Summary of Collaboration Revenue | Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Takeda Collaboration Agreement: Takeda Collaboration Agreement Services (1) $ 12,000 $ 7,142 $ 51,916 $ 14,172 Total Takeda Collaboration Revenue 12,000 7,142 51,916 14,172 Sanofi Collaboration Agreement CNS program license 40,000 — 40,000 — Peripheral Program License — 15,000 — 15,000 Alzheimer's Disease Services (2) — 3 — 4 Total Sanofi Collaboration Revenue 40,000 15,003 40,000 15,004 Biogen Collaboration Agreement Option Research Services (2) 480 794 2,705 1,686 Total Biogen Collaboration Revenue 480 794 2,705 $ 1,686 Total Collaboration Revenue $ 52,480 $ 22,939 $ 94,621 $ 30,862 _________________________________________________ (1) Revenue of $27.9 million and $11.8 million for the six months ended June 30, 2022 and 2021, respectively, were included in the contract liability balance at the beginning of the period. No revenue for the three months ended June 30, 2022, and all revenue for the three months ended June 30, 2021, were included in the contract liability balance at the beginning of the respective period. (2) Revenue for the three and six months ended June 30, 2022 and June 30, 2021 represent amounts that were included in the contract liability balance at the beginning of the respective period. |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Summary of Supplemental Information for Lease Amounts Recognized | The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating lease cost (1) $ 2,688 $ 2,777 $ 5,551 $ 5,566 Cash paid for amounts included in measurement of lease liability $ 2,676 $ 2,563 $ 5,294 $ 5,099 As of June 30, 2022 2021 Weighted average remaining lease term 6.8 years 7.8 years Weighted average discount rate 9% 9% __________________________________________________ (1) Including variable and short-term lease costs |
Summary of Future Minimum Lease Commitments | The following table reconciles the undiscounted cash flows for the next five years and total of the remaining years to the operating lease liability recorded in the Condensed Consolidated Balance Sheet as of June 30, 2022 (in thousands): Year Ended December 31: 2022 (six months) 5,408 2023 11,053 2024 11,417 2025 11,793 2026 12,182 Thereafter 29,966 Total undiscounted lease payments 81,819 Present value adjustment (20,423) Net operating lease liabilities $ 61,396 |
Summary of Future Minimum Lease Receivables | The following table details the future undiscounted cash inflows relating to the Sublease Agreement as of June 30, 2022 (in thousands): Year Ended December 31: 2022 (six months) 1,516 2023 3,096 2024 876 2025 and thereafter — Total undiscounted sublease receipts $ 5,488 |
Stock-Based Awards (Tables)
Stock-Based Awards (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Summary of Stock Option Activity | The following table summarizes stock option activity for the six months ended June 30, 2022: Number of Options Weighted-Average Exercise Price Balance at December 31, 2021 13,686,386 $ 24.33 Granted 2,099,590 43.97 Exercised (279,173) 12.66 Forfeited (348,281) 37.46 Balance at June 30, 2022 15,158,522 $ 26.96 Vested and expected to vest at June 30, 2022 13,485,327 $ 30.22 Exercisable at June 30, 2022 9,431,675 $ 20.27 |
Summary of Assumptions Used for Estimating the Fair Value of Stock Granted | The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions: Six Months Ended June 30, 2022 2021 Expected term (in years) 5.50 - 6.08 5.50 - 6.08 Volatility 65.1% - 66.1% 62.2% - 63.7% Risk-free interest rate 1.5% - 3.0% 0.5% - 1.1% Dividend yield — — |
Summary of Restricted Stock Activity | The following table summarizes restricted stock unit ("RSU") activity for the six months ended June 30, 2022: Number of RSU shares Weighted-Average Fair Value at Date of Grant per Share Unvested at December 31, 2021 2,629,980 $ 43.97 Granted 890,606 43.98 Vested and released (482,012) 43.44 Forfeited (139,832) 45.99 Unvested and expected to vest at June 30, 2022 2,898,742 $ 43.96 |
Summary of Stock-Based Compensation Expense | The Company’s results of operations include expenses relating to stock-based compensation as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 14,872 $ 12,509 $ 30,428 $ 24,823 General and administrative 9,064 8,627 19,653 17,341 Total $ 23,936 $ 21,136 $ 50,081 $ 42,164 |
Significant Accounting Polici_3
Significant Accounting Policies - Narrative (Details) $ in Millions | 6 Months Ended |
Jun. 30, 2022 USD ($) Segment | |
Accounting Policies [Abstract] | |
Number of operating segments | Segment | 1 |
Restricted cash | $ | $ 1.5 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Assets and Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Assets: | ||
Fair value | $ 1,007,800 | $ 997,379 |
Total | 1,100,862 | 1,262,673 |
Liabilities: | ||
Foreign currency derivative contracts | 111 | |
Total | 111 | |
Money market funds | ||
Assets: | ||
Cash equivalents | 93,062 | 265,294 |
Short-term marketable securities | U.S. government treasuries | ||
Assets: | ||
Fair value | 786,315 | 450,436 |
Short-term marketable securities | Corporate debt securities | ||
Assets: | ||
Fair value | 60,913 | 70,009 |
Short-term marketable securities | Commercial paper | ||
Assets: | ||
Fair value | 66,352 | 51,485 |
Long-term marketable securities | U.S. government treasuries | ||
Assets: | ||
Fair value | 92,279 | 410,147 |
Long-term marketable securities | Corporate debt securities | ||
Assets: | ||
Fair value | 1,941 | 15,302 |
Level 1 | ||
Assets: | ||
Total | 971,656 | 1,125,877 |
Liabilities: | ||
Foreign currency derivative contracts | 0 | |
Total | 0 | |
Level 1 | Money market funds | ||
Assets: | ||
Cash equivalents | 93,062 | 265,294 |
Level 1 | Short-term marketable securities | U.S. government treasuries | ||
Assets: | ||
Fair value | 786,315 | 450,436 |
Level 1 | Short-term marketable securities | Corporate debt securities | ||
Assets: | ||
Fair value | 0 | 0 |
Level 1 | Short-term marketable securities | Commercial paper | ||
Assets: | ||
Fair value | 0 | 0 |
Level 1 | Long-term marketable securities | U.S. government treasuries | ||
Assets: | ||
Fair value | 92,279 | 410,147 |
Level 1 | Long-term marketable securities | Corporate debt securities | ||
Assets: | ||
Fair value | 0 | 0 |
Level 2 | ||
Assets: | ||
Total | 129,206 | 136,796 |
Liabilities: | ||
Foreign currency derivative contracts | 111 | |
Total | 111 | |
Level 2 | Money market funds | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Level 2 | Short-term marketable securities | U.S. government treasuries | ||
Assets: | ||
Fair value | 0 | 0 |
Level 2 | Short-term marketable securities | Corporate debt securities | ||
Assets: | ||
Fair value | 60,913 | 70,009 |
Level 2 | Short-term marketable securities | Commercial paper | ||
Assets: | ||
Fair value | 66,352 | 51,485 |
Level 2 | Long-term marketable securities | U.S. government treasuries | ||
Assets: | ||
Fair value | 0 | 0 |
Level 2 | Long-term marketable securities | Corporate debt securities | ||
Assets: | ||
Fair value | 1,941 | 15,302 |
Level 3 | ||
Assets: | ||
Total | 0 | 0 |
Liabilities: | ||
Foreign currency derivative contracts | 0 | |
Total | 0 | |
Level 3 | Money market funds | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Level 3 | Short-term marketable securities | U.S. government treasuries | ||
Assets: | ||
Fair value | 0 | 0 |
Level 3 | Short-term marketable securities | Corporate debt securities | ||
Assets: | ||
Fair value | 0 | 0 |
Level 3 | Short-term marketable securities | Commercial paper | ||
Assets: | ||
Fair value | 0 | 0 |
Level 3 | Long-term marketable securities | U.S. government treasuries | ||
Assets: | ||
Fair value | 0 | 0 |
Level 3 | Long-term marketable securities | Corporate debt securities | ||
Assets: | ||
Fair value | $ 0 | $ 0 |
Marketable Securities - Summary
Marketable Securities - Summary of Available for Sale Securities (Details) $ in Thousands | Jun. 30, 2022 USD ($) security | Dec. 31, 2021 USD ($) security |
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | $ 1,019,723 | $ 999,527 |
Unrealized Holding Gains | 1 | 1 |
Unrealized Holding Losses | (11,924) | (2,149) |
Aggregate Fair Value | 1,007,800 | 997,379 |
Short-term marketable securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 922,620 | 572,250 |
Unrealized Holding Gains | 1 | 1 |
Unrealized Holding Losses | (9,041) | (321) |
Aggregate Fair Value | 913,580 | 571,930 |
Short-term marketable securities | U.S. government treasuries | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 794,785 | 450,689 |
Unrealized Holding Gains | 1 | 0 |
Unrealized Holding Losses | (8,471) | (253) |
Aggregate Fair Value | $ 786,315 | $ 450,436 |
Number of securities held in unrealized holding loss position | security | 55 | 19 |
Aggregate fair value, unrealized holding loss position | $ 746,800 | $ 450,400 |
Short-term marketable securities | Corporate debt securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 61,483 | 70,076 |
Unrealized Holding Gains | 0 | 1 |
Unrealized Holding Losses | (570) | (68) |
Aggregate Fair Value | $ 60,913 | $ 70,009 |
Number of securities held in unrealized holding loss position | security | 17 | 16 |
Aggregate fair value, unrealized holding loss position | $ 60,900 | $ 68,500 |
Short-term marketable securities | Commercial paper | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 66,352 | 51,485 |
Unrealized Holding Gains | 0 | 0 |
Unrealized Holding Losses | 0 | 0 |
Aggregate Fair Value | 66,352 | 51,485 |
Long-term marketable securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 97,103 | 427,277 |
Unrealized Holding Gains | 0 | 0 |
Unrealized Holding Losses | (2,883) | (1,828) |
Aggregate Fair Value | 94,220 | 425,449 |
Long-term marketable securities | U.S. government treasuries | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 95,099 | 411,904 |
Unrealized Holding Gains | 0 | 0 |
Unrealized Holding Losses | (2,820) | (1,757) |
Aggregate Fair Value | $ 92,279 | $ 410,147 |
Number of securities held in unrealized holding loss position | security | 6 | 16 |
Aggregate fair value, unrealized holding loss position | $ 92,300 | $ 410,100 |
Long-term marketable securities | Corporate debt securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 2,004 | 15,373 |
Unrealized Holding Gains | 0 | 0 |
Unrealized Holding Losses | (63) | (71) |
Aggregate Fair Value | $ 1,941 | $ 15,302 |
Number of securities held in unrealized holding loss position | security | 1 | 6 |
Aggregate fair value, unrealized holding loss position | $ 1,900 | $ 15,300 |
Marketable Securities - Narrati
Marketable Securities - Narrative (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Investments, Debt and Equity Securities [Abstract] | ||
Allowance for credit losses | $ 0 | $ 0 |
Effective maturity (less than) | 2 years |
Collaboration Agreements - Biog
Collaboration Agreements - Biogen (Details) | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2022 USD ($) milestone | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) milestone | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Research and development expense due to cost share payments to related party | [1] | $ 92,737,000 | $ 65,711,000 | $ 178,835,000 | $ 125,918,000 | |
Cost sharing reimbursements due from related party | 357,000 | 357,000 | $ 1,226,000 | |||
Collaboration revenue from customers | [2] | 52,480,000 | 22,936,000 | 94,621,000 | 30,858,000 | |
Biogen Collaboration Agreement | Related Party | ||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Contract liability | 291,000,000 | 291,000,000 | 293,700,000 | |||
Biogen Collaborative Arrangement | Biogen Collaboration Agreement | ||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Transaction price, change | 0 | 0 | ||||
Offset to research and development expense, related party cost reimbursement | 400,000 | $ 1,600,000 | 400,000 | $ 4,100,000 | ||
Research and development expense due to cost share payments to related party | 2,400,000 | 2,400,000 | ||||
Cost sharing reimbursements due from related party | $ 400,000 | $ 400,000 | $ 1,200,000 | |||
Number of milestones achieved | milestone | 0 | 0 | ||||
Biogen Collaborative Arrangement | Biogen Collaboration Agreement | Related Party | ||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Offset to research and development expense, related party cost reimbursement | $ 400,000 | |||||
Research and development expense due to cost share payments to related party | $ 2,400,000 | |||||
Biogen Collaborative Arrangement | Biogen Collaboration Agreement | Option Research Services | Related Party | ||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Contract liability | 2,100,000 | $ 2,100,000 | ||||
Biogen Collaborative Arrangement | Biogen Collaboration Agreement | Option Research Services | Related Party | Minimum | ||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Performance obligation, period | one year | |||||
Biogen Collaborative Arrangement | Biogen Collaboration Agreement | Product | ||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Collaboration revenue from customers | $ 0 | |||||
ROFN and Option Agreement | Biogen Collaboration Agreement | Material Right For An Option | Related Party | ||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Contract liability | $ 288,900,000 | $ 288,900,000 | ||||
ROFN and Option Agreement | Biogen Collaboration Agreement | Material Right For An Option | Related Party | Maximum | ||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
Performance obligation, period | one year | |||||
[1]Includes an offset to expense from related-party cost sharing reimbursements of $0.4 million and expense for cost sharing payments to a related party of $2.4 million for the three and six months ended June 30, 2022, respectively, and an offset to expense from related-party cost sharing reimbursements of $1.6 million and $4.1 million for the three and six months ended June 30, 2021, respectively.[2]Includes related-party collaboration revenue from a customer of $0.5 million and $2.7 million for the three and six months ended June 30, 2022, respectively, and $0.8 million and $1.7 million for the three and six months ended June 30, 2021, respectively. |
Collaboration Agreements - Sano
Collaboration Agreements - Sanofi (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 45 Months Ended | ||||
Apr. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Dec. 31, 2021 | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Collaboration revenue from customers | [1] | $ 52,480,000 | $ 22,936,000 | $ 94,621,000 | $ 30,858,000 | |||
Sanofi | Collaborative Arrangement | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Transaction price, change | 40,000,000 | 40,000,000 | ||||||
Receivable | 0 | 0 | $ 0 | $ 0 | ||||
Sanofi | Collaborative Arrangement | Alzheimer's Disease Services | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Contract liability | $ 3,400,000 | $ 3,400,000 | 3,400,000 | $ 3,400,000 | ||||
Sanofi | Collaborative Arrangement | Milestone Triggered | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Collaboration revenue from customers | $ 40,000,000 | 65,000,000 | ||||||
Sanofi | Collaborative Arrangement | Product | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Collaboration revenue from customers | $ 0 | |||||||
[1]Includes related-party collaboration revenue from a customer of $0.5 million and $2.7 million for the three and six months ended June 30, 2022, respectively, and $0.8 million and $1.7 million for the three and six months ended June 30, 2021, respectively. |
Collaboration Agreements - Take
Collaboration Agreements - Takeda (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 54 Months Ended | ||||
Dec. 31, 2021 USD ($) contract | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) milestone | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Collaboration revenue from customers | [1] | $ 52,480,000 | $ 22,936,000 | $ 94,621,000 | $ 30,858,000 | |||
Prepaid expenses and other current assets | $ 30,601,000 | 45,575,000 | 45,575,000 | $ 45,575,000 | ||||
Collaborative Arrangement | Takeda Pharmaceutical Company Limited | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Possible preclinical milestone payments (up to) | 55,000,000 | 55,000,000 | 55,000,000 | |||||
Collaboration revenue from customers | $ 12,000,000 | |||||||
Collaborative arrangement, number of preclinical milestones | milestone | 2 | |||||||
Receivable | $ 0 | |||||||
Remaining performance obligation | 0 | $ 0 | 0 | |||||
Collaborative Arrangement | Takeda Pharmaceutical Company Limited | Milestone Triggered | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Milestone payments received | 43,000,000 | |||||||
Collaboration revenue from customers | 55,000,000 | |||||||
Transaction price, change | 12,000,000 | 24,000,000 | ||||||
Collaborative Arrangement | Takeda Pharmaceutical Company Limited | Product | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Collaboration revenue from customers | 0 | |||||||
Collaborative Arrangement, PTV:PGRN and ATV:TREM2 | Takeda Pharmaceutical Company Limited | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Transaction price, change | 0 | 0 | ||||||
Number of new contracts | contract | 2 | |||||||
Offset to research and development expense, cost reimbursement | $ 0 | $ 0 | ||||||
Collaborative Arrangement, PTV:PGRN and ATV:TREM2 | Takeda Pharmaceutical Company Limited | Maximum | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Aggregate payments due upon achievement of certain clinical milestone events | $ 280,000,000 | |||||||
Aggregate payments upon achievement of certain regulatory milestone events | 200,000,000 | |||||||
Milestone payments per biologic product upon achievement of a certain sales-based milestone | 75,000,000 | |||||||
Aggregate sales-based milestone payments, if one biologic product from each program achieves milestone | 150,000,000 | |||||||
Collaborative Arrangement, PTV:PGRN and ATV:TREM2 | Takeda Pharmaceutical Company Limited | Option Fee Payment | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Collaboration revenue from customers | 10,000,000 | |||||||
Collaborative Arrangement, PTV:PGRN and ATV:TREM2 | Takeda Pharmaceutical Company Limited | Product | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Collaboration revenue from customers | 0 | |||||||
Collaborative Arrangement, PTV:PGRN | Takeda Pharmaceutical Company Limited | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Offset to research and development expense, cost reimbursement | 2,800,000 | 5,700,000 | ||||||
Collaborative Arrangement, ATV:TREM2 | Takeda Pharmaceutical Company Limited | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Offset to research and development expense, cost reimbursement | 1,500,000 | 3,600,000 | ||||||
Collaborative Arrangement, ATV:TREM2 | Takeda Pharmaceutical Company Limited | Prepaid Expenses and Other Current Assets | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Preclinical milestone payment earned not yet received | 12,000,000 | 12,000,000 | 12,000,000 | |||||
Collaborative Arrangement, ATV:Tau | Takeda Pharmaceutical Company Limited | ||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||
Collaboration revenue from customers | $ 27,900,000 | |||||||
Contract liability | $ 27,900,000 | $ 0 | $ 0 | $ 0 | ||||
[1]Includes related-party collaboration revenue from a customer of $0.5 million and $2.7 million for the three and six months ended June 30, 2022, respectively, and $0.8 million and $1.7 million for the three and six months ended June 30, 2021, respectively. |
Collaboration Agreements - Summ
Collaboration Agreements - Summary of Collaboration Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Collaborative revenue, revenue from contract with customer | [1] | $ 52,480 | $ 22,936 | $ 94,621 | $ 30,858 |
Collaborative revenue, excluding revenue from contract with customer | 0 | 3 | 0 | 4 | |
Total Collaboration Revenue | 52,480 | 22,939 | 94,621 | 30,862 | |
Takeda Collaboration Agreement | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Total Collaboration Revenue | 12,000 | 7,142 | 51,916 | 14,172 | |
Revenue recognized included in the contract liability balance at the beginning of the period | 0 | 27,900 | 11,800 | ||
Takeda Collaboration Agreement | Collaboration Agreement Services | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Collaborative revenue, revenue from contract with customer | 12,000 | 7,142 | 51,916 | 14,172 | |
Sanofi Collaboration Agreement | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Total Collaboration Revenue | 40,000 | 15,003 | 40,000 | 15,004 | |
Sanofi Collaboration Agreement | CNS program license | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Collaborative revenue, revenue from contract with customer | 40,000 | 0 | 40,000 | 0 | |
Sanofi Collaboration Agreement | Peripheral Program License | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Collaborative revenue, revenue from contract with customer | 0 | 15,000 | 0 | 15,000 | |
Sanofi Collaboration Agreement | Alzheimer's Disease Services | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Collaborative revenue, excluding revenue from contract with customer | 0 | 3 | 0 | 4 | |
Biogen Collaboration Agreement | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Total Collaboration Revenue | 480 | 794 | 2,705 | 1,686 | |
Biogen Collaboration Agreement | Option Research Services | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Collaborative revenue, revenue from contract with customer | $ 480 | $ 794 | $ 2,705 | $ 1,686 | |
[1]Includes related-party collaboration revenue from a customer of $0.5 million and $2.7 million for the three and six months ended June 30, 2022, respectively, and $0.8 million and $1.7 million for the three and six months ended June 30, 2021, respectively. |
License Agreements - Narrative
License Agreements - Narrative (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 73 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||
Research and development | [1] | $ 92,737,000 | $ 65,711,000 | $ 178,835,000 | $ 125,918,000 | ||
Genentech Inc | License Agreement | Research and development | |||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||
Clinical milestone payment | $ 7,500,000 | $ 0 | $ 0 | ||||
Aggregate payments | $ 20,000,000 | ||||||
Genentech Inc | Collaborative Arrangement | |||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||
Research and development | $ 3,800,000 | $ 3,800,000 | |||||
Biogen | License Agreement | |||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||
Research and development | $ 16,300,000 | ||||||
Biogen | Collaborative Arrangement | |||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||
Percentage of costs reimbursed by biogen | 50% | 50% | |||||
[1]Includes an offset to expense from related-party cost sharing reimbursements of $0.4 million and expense for cost sharing payments to a related party of $2.4 million for the three and six months ended June 30, 2022, respectively, and an offset to expense from related-party cost sharing reimbursements of $1.6 million and $4.1 million for the three and six months ended June 30, 2021, respectively. |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) ft² in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
Jul. 31, 2022 ft² | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jul. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Loss Contingencies [Line Items] | |||||||
Sublease income | $ 900,000 | $ 1,000,000 | $ 1,900,000 | $ 1,900,000 | |||
DMSA | |||||||
Loss Contingencies [Line Items] | |||||||
Purchase order executed | 41,400,000 | 41,400,000 | $ 35,800,000 | ||||
Non-refundable purchase commitments | 25,200,000 | 25,200,000 | $ 28,300,000 | ||||
Costs incurred | 9,500,000 | 3,200,000 | 19,500,000 | 8,400,000 | |||
Payments for development and manufacturing services | 7,000,000 | $ 5,700,000 | 15,700,000 | $ 6,400,000 | |||
Building | SLC Lease | |||||||
Loss Contingencies [Line Items] | |||||||
Lease not yet commenced, lease liability | 0 | 0 | |||||
Lease not yet commenced, ROU asset | 0 | 0 | |||||
Lease not yet commenced, operating lease expense | $ 0 | $ 0 | |||||
Building | SLC Lease | Operating Lease, 9.3 Year Lease Agreement | Subsequent Event | |||||||
Loss Contingencies [Line Items] | |||||||
Lease not yet commenced, area under lease | ft² | 78 | ||||||
Lease not yet commenced, period | 9 years 3 months 18 days | ||||||
Lease not yet commenced, undiscounted lease payments | $ 20,000,000 |
Commitments and Contingencies_2
Commitments and Contingencies - Summary of Supplemental Lease Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | ||||
Operating lease cost | $ 2,688 | $ 2,777 | $ 5,551 | $ 5,566 |
Cash paid for amounts included in measurement of lease liability | $ 2,676 | $ 2,563 | $ 5,294 | $ 5,099 |
Weighted average remaining lease term | 6 years 9 months 18 days | 7 years 9 months 18 days | 6 years 9 months 18 days | 7 years 9 months 18 days |
Weighted average discount rate | 9% | 9% | 9% | 9% |
Commitments and Contingencies_3
Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details) $ in Thousands | Jun. 30, 2022 USD ($) |
Operating Lease Liabilities, Payments Due [Abstract] | |
2022 (six months) | $ 5,408 |
2023 | 11,053 |
2024 | 11,417 |
2025 | 11,793 |
2026 | 12,182 |
Thereafter | 29,966 |
Total undiscounted lease payments | 81,819 |
Present value adjustment | (20,423) |
Net operating lease liabilities | $ 61,396 |
Commitments and Contingencies_4
Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details) $ in Thousands | Jun. 30, 2022 USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
2022 (six months) | $ 1,516 |
2023 | 3,096 |
2024 | 876 |
2025 and thereafter | 0 |
Total undiscounted sublease receipts | $ 5,488 |
Stock-Based Awards - Summary of
Stock-Based Awards - Summary of Stock Option Activity (Details) | 6 Months Ended |
Jun. 30, 2022 $ / shares shares | |
Number of Options | |
Beginning balance (in shares) | shares | 13,686,386 |
Granted (in shares) | shares | 2,099,590 |
Exercised (in shares) | shares | (279,173) |
Forfeited (in shares) | shares | (348,281) |
Ending balance (in shares) | shares | 15,158,522 |
Vested and expected to vest (in shares) | shares | 13,485,327 |
Exercisable (in shares) | shares | 9,431,675 |
Weighted-Average Exercise Price | |
Beginning balance (usd per share) | $ / shares | $ 24.33 |
Granted (usd per share) | $ / shares | 43.97 |
Exercised (usd per share) | $ / shares | 12.66 |
Forfeited (usd per share) | $ / shares | 37.46 |
Ending balance (usd per share) | $ / shares | 26.96 |
Vested and expected to vest (usd per share) | $ / shares | 30.22 |
Exercisable (usd per share) | $ / shares | $ 20.27 |
Stock-Based Awards - Summary _2
Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details) | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term (in years) | 5 years 6 months | 5 years 6 months |
Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term (in years) | 6 years 29 days | 6 years 29 days |
Stock Options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility, minimum | 65.10% | 62.20% |
Volatility, maximum | 66.10% | 63.70% |
Risk-free interest rate, minimum | 1.50% | 0.50% |
Risk-free interest rate, maximum | 3% | 1.10% |
Dividend yield | 0% | 0% |
Stock-Based Awards - Summary _3
Stock-Based Awards - Summary of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) | 6 Months Ended |
Jun. 30, 2022 $ / shares shares | |
Number of RSU shares | |
Unvested at December 31, 2021 (in shares) | shares | 2,629,980 |
Granted (in shares) | shares | 890,606 |
Vested and released (in shares) | shares | (482,012) |
Forfeited (in shares) | shares | (139,832) |
Unvested at June 30, 2022 (in shares) | shares | 2,898,742 |
Expected to vest at June 30, 2022 (in shares) | shares | 2,898,742 |
Weighted-Average Fair Value at Date of Grant per Share | |
Unvested at December 31, 2021 (usd per share) | $ / shares | $ 43.97 |
Granted (usd per share) | $ / shares | 43.98 |
Vested and released (usd per share) | $ / shares | 43.44 |
Forfeited (usd per share) | $ / shares | 45.99 |
Unvested at June 30, 2022 (usd per share) | $ / shares | 43.96 |
Expected to vest at June 30, 2022 (usd per share) | $ / shares | $ 43.96 |
Stock-Based Awards - Summary _4
Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Total | $ 23,936 | $ 21,136 | $ 50,081 | $ 42,164 |
Research and development | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Total | 14,872 | 12,509 | 30,428 | 24,823 |
General and administrative | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Total | $ 9,064 | $ 8,627 | $ 19,653 | $ 17,341 |
Net Loss Per Share - Schedule o
Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details) - shares shares in Millions | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Earnings Per Share [Abstract] | ||
Antidilutive securities, excluded (in shares) | 18.4 | 16.7 |